Charting the Global Biosimialr pipeline
There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche's Avastin (bevacizumab), Abbvie's Humira (adalimumab) and Janssen/Merck & Co's Remicade (infliximab) are being targeted by multiple biosimilar developers. But which companies are leading the market? What products are being targeted? Where is development geographically concentrated? What licensing and collaboration opportunities are there?
The answers to these and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation of the biosimilar development landscape worldwide. Rich in tables, charts and statistics, it delivers the critical data you need to understand trends, identify opportunities and assess competitive threats.
Discover on this page
What is the true potential of the much hyped biosimilar market? At present there are 260 biosimilar products which are approved in at least one market – and many of those are first generation products such as hormones. The future, however, is looking more interesting with 188 biosimilars in development, 61 of which are in Phase III trials. The number of high value mAbs for a wide range of conditions has increased. Development continues to be concentrated in countries such as India, China, Bangladesh, Iran and South Korea. In contrast, high development cost, originator defence strategies and more stringent regulatory regimes are pegging back development interest in the US and Europe. In the US there are 6 companies with 8 biosimilars registered . The sector is dominated by originator companies such as Pfizer, Amgen and Merck & Co. Europe is scarcely better with 9 companies and 13 biosimilars registered. The global biosimilar market is maturing both in its scope and ambitions.
Use this report to
This detailed 432 page report has been organised to give rapid access to, where relevant and available, the key information
Overview
Each biosimilar monograph utilises well-structured tables and charts to provide clear view of
Details provided, where available
Each company monograph utilises well-structured tables and charts to provide, where relevant and available, a clear view of
Details provided, where available
The answers to these and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation of the biosimilar development landscape worldwide. Rich in tables, charts and statistics, it delivers the critical data you need to understand trends, identify opportunities and assess competitive threats.
Discover on this page
- Why this report is important
- What the report can do for you
- Report contents
What is the true potential of the much hyped biosimilar market? At present there are 260 biosimilar products which are approved in at least one market – and many of those are first generation products such as hormones. The future, however, is looking more interesting with 188 biosimilars in development, 61 of which are in Phase III trials. The number of high value mAbs for a wide range of conditions has increased. Development continues to be concentrated in countries such as India, China, Bangladesh, Iran and South Korea. In contrast, high development cost, originator defence strategies and more stringent regulatory regimes are pegging back development interest in the US and Europe. In the US there are 6 companies with 8 biosimilars registered . The sector is dominated by originator companies such as Pfizer, Amgen and Merck & Co. Europe is scarcely better with 9 companies and 13 biosimilars registered. The global biosimilar market is maturing both in its scope and ambitions.
Use this report to
- Profile the most active biosimilar companies and their pipelines
- Know the development status of biosimilars targeting high-value brands and the companies that are involved
- Identify licensing and collaboration opportunities
- Assess the clinical trials that are underpinning biosimilar development
- Review 61 biosimilar projects in Phase III and anticipate where they will make a market impact
- Establish where biosimilar development around the world is concentrated and evaluate the companies driving progress
This detailed 432 page report has been organised to give rapid access to, where relevant and available, the key information
Overview
- Biosimilars by therapy area
- Biosimilars by product class
- Most popular/bestselling biosimilar product candidates
- Biosimilars by development stage
- Leading biosimilar companies
- Biosimilar pipeline by product
Each biosimilar monograph utilises well-structured tables and charts to provide clear view of
Details provided, where available
- Class
- Mode of action
- Key therapeutic area(s)
- Route of administration
- Reference product
- Originator
- RP sales
- RP indications
- US/EU patent information
- Number of companies developing this biosimilar
- Summary of biosimilar products in development by status, brand/lab code, company and location
- Biosimilar product approvals by territory, molecule, biosimilar company, approval date and biosimilar brand name
- Comprehensive summary of clinical trial activity including company, product code, trial code, phase, indication, patients enrolled, and estimated study completion dates
- Abatacept
- Abciximab
- Adalimumab
- Aflibercept
- Anakinra
- Bevacizumab
- Certolizumab Pegol
- Cetuximab
- Daclizumab
- Darbepoetin Alfa
- Denosumab
- Eculizumab
- Enoxaparin
- Epoetin Alfa
- Etanercept
- Filgrastim
- Follitropin Alfa
- Infliximab
- Insulin Aspart
- Insulin Glargine
- Insulin (Human)
- Insulin Lispro
- Interferon Alfa-2A
- Interferon Alfa-2B
- Interferon Beta-1A
- Interferon Beta-1B
- Interleukin-2
- Interleukin-11
- Omalizumab
- Palivizumab
- Pegfilgrastim
- Peginterferon Alfa-2A
- Peginterferon Alfa-2B
- Pertuzumab
- Ranibizumab
- Rituximab
- Somatropin
- Teriparatide
- Tocilizumab
- Trastuzumab
- Ustekinumab
- Vedolizumab
Each company monograph utilises well-structured tables and charts to provide, where relevant and available, a clear view of
Details provided, where available
- Class
- Mode of action
- Key therapeutic area(s)
- Route of administration
- Reference product
- Originator
- RP sales
- RP indications
- US/EU Patent information
- Number of companies developing this biosimilar
- Biosimilar development status
- Biosimilar brand/lab code
- Biosimilar developer(s)
- Location of biosimilar developer(s)
- Accord Healthcare
- Adello Biologics
- Alteogen
- Amgen
- Apotex
- Aprogen
- Archigen Biotech
- Biocad
- Biocon/Mylan
- Boehringer Ingelheim
- Celltrion
- Centus Biotherapeutics
- Cipla
- Coherus Biosciences
- Dem Ilaç
- Dr Reddy's
- Epirus Biopharmaceuticals
- Finox Biotech
- Formycon AG
- Fresenius
- Fuji Pharma
- Fujifilm Kyowa Kirin Biologics
- Glenmark
- Hanwha Chemical
- Intas
- JCR Pharmaceuticals
- JHL Biotech
- LG Chem/LG Life Sciences
- Lilly
- Mabion
- mAbxience
- Merck & Co
- Mochida
- Momenta
- Nichi-Iko
- Nippon Kayaku
- Pfenex
- Pfizer
- Pharmathen
- Prestige Biopharma
- Reliance Life Sciences
- Rovi
- Samsung Bioepsis
- Sandoz
- Sanofi
- Stada Arzneimittel
- Techdow Europe AB
- Teva
- Torrent Pharmaceuticals
- USV
- Wockhardt
- YL Biologics
- Zydus Cadila
1. REPORT METHODOLOGY AND OBJECTIVES
1.1 Key data sources
1.1.1 Clinical trials
1.1.2 Company data
1.1.3 Investment reports
1.1.4 Conference proceedings
1.1.5 Social media
2. OVERVIEW
2.1 Biosimilars by therapy area
2.2 Biosimilars by product class
2.3 Most popular/bestselling biosimilar product candidates
2.4 Biosimilars by development stage
2.5 Leading biosimilar companies
3. BIOSIMILAR PIPELINE BY PRODUCT
3.1 Abatacept
3.2 Abciximab
3.3 Adalimumab
3.4 Aflibercept
3.5 Anakinra
3.6 Bevacizumab
3.7 Certolizumab pegol
3.8 Cetuximab
3.9 Daclizumab
3.10 Darbepoetin alfa
3.11 Denosumab
3.12 Eculizumab
3.13 Enoxaparin
3.14 Epoetin alfa
3.15 Etanercept
3.16 Filgrastim
3.17 Follitropin alfa
3.18 Infliximab
3.19 Insulin aspart
3.20 Insulin glargine
3.21 Insulin (human)
3.22 Insulin lispro
3.23 Interferon alfa-2A
3.24 Interferon alfa-2B
3.25 Interferon beta-1A
3.26 Interferon beta-1B
3.27 Interleukin-2
3.28 Interleukin-11
3.29 Omalizumab
3.30 Palivizumab
3.31 Pegfilgrastim
3.32 Peginterferon alfa-2A
3.33 Peginterferon alfa-2B
3.34 Pertuzumab
3.35 Ranibizumab
3.36 Rituximab
3.37 Somatropin
3.38 Teriparatide
3.39 Tocilizumab
3.40 Trastuzumab
3.41 Ustekinumab
3.42 Vedolizumab
4. BIOSIMILAR PIPELINES BY COMPANY
4.1 Accord Healthcare
4.1.1 Product and pipeline status
4.1.2 Product approvals
4.2 Adello Biologics
4.2.1 Product and pipeline status
4.3 Alteogen
4.3.1 Product and pipeline status
4.4 Amgen
4.4.1 Product and pipeline status
4.4.2 Product approvals
4.5 Apotex
4.5.1 Product and pipeline status
4.5.2 Product approvals
4.6 Aprogen
4.6.1 Product and pipeline status
4.7 Archigen Biotech
4.7.1 Product and pipeline status
4.8 Biocad
4.8.1 Product and pipeline status
4.8.2 Product approvals
4.9 Biocon/Mylan
4.9.1 Product and pipeline status
4.9.2 Product approvals
4.10 Boehringer Ingelheim
4.10.1 Product and pipeline status
4.10.2 Product approvals
4.11 Celltrion
4.11.1 Product and pipeline status
4.11.2 Product approvals
4.12 Centus Biotherapeutics
4.12.1 Product and pipeline status
4.13 Cipla
4.13.1 Product and pipeline status
4.14 Coherus Biosciences
4.14.1 Product and pipeline status
4.15 Dem Ilaç
4.15.1 Product and pipeline status
4.16 Dr Reddy’s
4.16.1 Product and pipeline status
4.17 Epirus Biopharmaceuticals
4.17.1 Product and pipeline status
4.17.2 Product approvals
4.18 Finox Biotech
4.18.1 Product and pipeline status
4.18.2 Product approvals
4.19 Formycon AG
4.19.1 Product and pipeline status
4.20 Fresenius
4.20.1 Product and pipeline status
4.21 Fuji Pharma
4.21.1 Product and pipeline status
4.22Fujifilm Kyowa Kirin Biologics
4.22.1 Product and pipeline status
4.23 Glenmark
4.23.1 Product and pipeline status
4.24 Hanwha Chemical
4.24.1 Product and pipeline status
4.24.2 Product approvals
4.25 Intas
4.25.1 Product and pipeline status
4.25.2 Product approvals
4.26 JCR Pharmaceuticals
4.26.1 Product and pipeline status
4.26.2 Product approvals
4.27 JHL Biotech
4.27.1 Product and pipeline status
4.28 LG Chem/LG Life Sciences
4.28.1 Product and pipeline status
4.29 Lilly
4.29.1 Product and pipeline status
4.29.2 Product approvals
4.30 Mabion
4.30.1 Product and pipeline status
4.31 mAbxience
4.31.1 Product and pipeline status
4.32 Merck & Co
4.32.1 Product and pipeline status
4.32.2 Product approvals
4.33 Mochida
4.33.1 Product and pipeline status
4.33.2 Product approvals
4.34 Momenta
4.34.1 Product and pipeline status
4.35 Nichi-IkoProduct and pipeline status
4.35.1 Product approvals
4.36 Nippon Kayaku
4.36.1 Product and pipeline status
4.36.2 Product approvals
4.37 Pfenex
4.37.1 Product and pipeline status
4.38 Pfizer
4.38.1 Product and pipeline status
4.39 Pharmathen
4.39.1 Product and pipeline status
4.39.2 Product approvals
4.40 Prestige Biopharma
4.40.1 Product and pipeline status
4.41 Reliance Life Sciences
4.41.1 Product and pipeline status
4.41.2 Product approvals
4.42 Rovi
4.42.1 Product and pipeline status
4.43 Samsung Bioepsis
4.43.1 Product and pipeline status
4.43.2 Product approvals
4.44 Sandoz (Novartis)
4.44.1 Product and pipeline status
4.44.2 Product approvals
4.45 Sanofi
4.45.1 Product and pipeline status
4.45.2 Product approvals
4.46 Stada Arzneimittel
4.46.1 Product and pipeline status
4.46.2 Product approvals
4.47 Techdow Europe AB
4.47.1 Product and pipeline status
4.47.2 Product approvals
4.48 Teva
4.48.1 Product and pipeline status
4.48.2 Product approvals
4.49 Torrent Pharmaceuticals
4.49.1 Product and pipeline status
4.50 USV
4.50.1 Product and pipeline status
4.51 Wockhardt
4.51.1 Product and pipeline status
4.52 YL Biologics
4.52.1 Product and pipeline status
4.53 Zydus Cadila
4.53.1 Product and pipeline status
4.53.2 Product approvals
1.1 Key data sources
1.1.1 Clinical trials
1.1.2 Company data
1.1.3 Investment reports
1.1.4 Conference proceedings
1.1.5 Social media
2. OVERVIEW
2.1 Biosimilars by therapy area
2.2 Biosimilars by product class
2.3 Most popular/bestselling biosimilar product candidates
2.4 Biosimilars by development stage
2.5 Leading biosimilar companies
3. BIOSIMILAR PIPELINE BY PRODUCT
3.1 Abatacept
3.2 Abciximab
3.3 Adalimumab
3.4 Aflibercept
3.5 Anakinra
3.6 Bevacizumab
3.7 Certolizumab pegol
3.8 Cetuximab
3.9 Daclizumab
3.10 Darbepoetin alfa
3.11 Denosumab
3.12 Eculizumab
3.13 Enoxaparin
3.14 Epoetin alfa
3.15 Etanercept
3.16 Filgrastim
3.17 Follitropin alfa
3.18 Infliximab
3.19 Insulin aspart
3.20 Insulin glargine
3.21 Insulin (human)
3.22 Insulin lispro
3.23 Interferon alfa-2A
3.24 Interferon alfa-2B
3.25 Interferon beta-1A
3.26 Interferon beta-1B
3.27 Interleukin-2
3.28 Interleukin-11
3.29 Omalizumab
3.30 Palivizumab
3.31 Pegfilgrastim
3.32 Peginterferon alfa-2A
3.33 Peginterferon alfa-2B
3.34 Pertuzumab
3.35 Ranibizumab
3.36 Rituximab
3.37 Somatropin
3.38 Teriparatide
3.39 Tocilizumab
3.40 Trastuzumab
3.41 Ustekinumab
3.42 Vedolizumab
4. BIOSIMILAR PIPELINES BY COMPANY
4.1 Accord Healthcare
4.1.1 Product and pipeline status
4.1.2 Product approvals
4.2 Adello Biologics
4.2.1 Product and pipeline status
4.3 Alteogen
4.3.1 Product and pipeline status
4.4 Amgen
4.4.1 Product and pipeline status
4.4.2 Product approvals
4.5 Apotex
4.5.1 Product and pipeline status
4.5.2 Product approvals
4.6 Aprogen
4.6.1 Product and pipeline status
4.7 Archigen Biotech
4.7.1 Product and pipeline status
4.8 Biocad
4.8.1 Product and pipeline status
4.8.2 Product approvals
4.9 Biocon/Mylan
4.9.1 Product and pipeline status
4.9.2 Product approvals
4.10 Boehringer Ingelheim
4.10.1 Product and pipeline status
4.10.2 Product approvals
4.11 Celltrion
4.11.1 Product and pipeline status
4.11.2 Product approvals
4.12 Centus Biotherapeutics
4.12.1 Product and pipeline status
4.13 Cipla
4.13.1 Product and pipeline status
4.14 Coherus Biosciences
4.14.1 Product and pipeline status
4.15 Dem Ilaç
4.15.1 Product and pipeline status
4.16 Dr Reddy’s
4.16.1 Product and pipeline status
4.17 Epirus Biopharmaceuticals
4.17.1 Product and pipeline status
4.17.2 Product approvals
4.18 Finox Biotech
4.18.1 Product and pipeline status
4.18.2 Product approvals
4.19 Formycon AG
4.19.1 Product and pipeline status
4.20 Fresenius
4.20.1 Product and pipeline status
4.21 Fuji Pharma
4.21.1 Product and pipeline status
4.22Fujifilm Kyowa Kirin Biologics
4.22.1 Product and pipeline status
4.23 Glenmark
4.23.1 Product and pipeline status
4.24 Hanwha Chemical
4.24.1 Product and pipeline status
4.24.2 Product approvals
4.25 Intas
4.25.1 Product and pipeline status
4.25.2 Product approvals
4.26 JCR Pharmaceuticals
4.26.1 Product and pipeline status
4.26.2 Product approvals
4.27 JHL Biotech
4.27.1 Product and pipeline status
4.28 LG Chem/LG Life Sciences
4.28.1 Product and pipeline status
4.29 Lilly
4.29.1 Product and pipeline status
4.29.2 Product approvals
4.30 Mabion
4.30.1 Product and pipeline status
4.31 mAbxience
4.31.1 Product and pipeline status
4.32 Merck & Co
4.32.1 Product and pipeline status
4.32.2 Product approvals
4.33 Mochida
4.33.1 Product and pipeline status
4.33.2 Product approvals
4.34 Momenta
4.34.1 Product and pipeline status
4.35 Nichi-IkoProduct and pipeline status
4.35.1 Product approvals
4.36 Nippon Kayaku
4.36.1 Product and pipeline status
4.36.2 Product approvals
4.37 Pfenex
4.37.1 Product and pipeline status
4.38 Pfizer
4.38.1 Product and pipeline status
4.39 Pharmathen
4.39.1 Product and pipeline status
4.39.2 Product approvals
4.40 Prestige Biopharma
4.40.1 Product and pipeline status
4.41 Reliance Life Sciences
4.41.1 Product and pipeline status
4.41.2 Product approvals
4.42 Rovi
4.42.1 Product and pipeline status
4.43 Samsung Bioepsis
4.43.1 Product and pipeline status
4.43.2 Product approvals
4.44 Sandoz (Novartis)
4.44.1 Product and pipeline status
4.44.2 Product approvals
4.45 Sanofi
4.45.1 Product and pipeline status
4.45.2 Product approvals
4.46 Stada Arzneimittel
4.46.1 Product and pipeline status
4.46.2 Product approvals
4.47 Techdow Europe AB
4.47.1 Product and pipeline status
4.47.2 Product approvals
4.48 Teva
4.48.1 Product and pipeline status
4.48.2 Product approvals
4.49 Torrent Pharmaceuticals
4.49.1 Product and pipeline status
4.50 USV
4.50.1 Product and pipeline status
4.51 Wockhardt
4.51.1 Product and pipeline status
4.52 YL Biologics
4.52.1 Product and pipeline status
4.53 Zydus Cadila
4.53.1 Product and pipeline status
4.53.2 Product approvals
